Search results :

Tenofovir disoproxil fumarate

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: J05AF07

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13
Pruritus 16% x x x x x x x x x x
Nasopharyngitis 9.86% - 11.2% x x x x x x
Nausea postmarketing — 2.79% - 20% 5% - 10% x x x x x x x x x x x x x
Fasting 2% - 24% x x x x x
Pain 7% - 12% 7% x x x x x x x x x x
Diarrhoea postmarketing — 5.12% - 16% 8% - 10% x x x x x x x x x x x x x
Fatigue 7.44% - 8.45% x x x x x x
Asthenia postmarketing — 7% - 11% 6% - 8% x x x x x x x x x x x x x
Headache 5% - 14% 5% - 7% x x x x x x x x x x x x
Abdominal pain upper 5.12% - 7.04% x x
Depression 4% - 8% 3% x x x x x x x x x x
Vomiting postmarketing — 4% - 13% 1% - 2% x x x x x x x x x x x x x
Procedural pain 3.76% - 5.58% x
Back pain 3% - 7.04% 3% x x x x x x x x x x
Pharyngolaryngeal pain 3.52% - 5.12% x
Upper respiratory tract infection 3.05% - 5.12% x x x x x x
Body temperature increased 2% - 11% 2% x x x x x x x x x x
Flatulence postmarketing — 3% - 4% 0% - 1% x x x x x x x x x x x x x
Neuropathy peripheral 3% - 5% 3% x x x x x x x x x x
Insomnia 3% - 18% 2% x x x x x x x x x x
Dyspepsia 3% - 4% 2% x x x x x x x x x x
Myalgia 3% - 4% 3% x x x x x x x x x x
Dizziness postmarketing — 1% - 13% 3% x x x x x x x x x x x x
Anorexia 3% - 4% 1% - 2% x x x x x x x x x x x x
Chest pain 3% 1% x x x x x x x x x x
Sweating 3% 2% x x x x x x x x x x
Weight decreased 2% - 4% 1% x x x x x x x x x x
Transaminases increased postmarketing, common x
Pneumonia 2% - 3% 0% x x x x x x x x x x
Haematuria 2% - 3% x x x x x x x x x x
Glycosuria 1% - 3% x x
Hyperglycaemia postmarketing, 1% - 2% x x x x x x x
Abdominal pain postmarketing, 3% - 22% 3% x x x x x x x x x x x x
Lactic acidosis postmarketing, rare x x x x x x x x x x x x
Angioedema postmarketing, rare x x
Autoimmune disorder postmarketing x
Connective tissue disorder postmarketing x x x x x x
Dyspnoea postmarketing x x x x x x x x x x x
Rash postmarketing — 5% - 7% 4% x x x x x x x x x x x x
Fanconi syndrome postmarketing, rare x x x x x x x x x x x x
Fracture postmarketing, rare x x x
Gastrointestinal disorder postmarketing x x x x x x x x x x x
Basedow's disease postmarketing x
Hepatitis postmarketing, rare x x x x x x x x x
Hepatomegaly postmarketing x x
Hypercholesterolaemia postmarketing x
Hypersensitivity postmarketing x x x x x x x x x x
Hypertriglyceridaemia postmarketing x
Hypertrophy of breast postmarketing x
Hypokalaemia postmarketing, uncommon x x x
Immune system disorder postmarketing x x x x x x x x x x
Inflammation postmarketing x x x
Insulin resistance postmarketing x
Renal failure acute postmarketing, rare x x x x x x x x x x x
Nephrosis lower nephron postmarketing, rare x x x x x x x x x x x
Lipodystrophy postmarketing x x x x x x x x x
Mediastinal disorder postmarketing x x x x x x x x x x
Myopathy postmarketing, rare x x x x x x
Nephritis postmarketing, rare x x
Nephritis interstitial postmarketing x x x x x
Nervous system disorder postmarketing x x x x x x x
Opportunistic infection postmarketing x
Osteomalacia postmarketing, rare x x x x x x
Osteonecrosis postmarketing x
Pancreatitis postmarketing, uncommon x x x x x x x x x x x x
Polyuria postmarketing x x x x x x
Proteinuria postmarketing x x x x x x x x x x
Renal failure postmarketing, rare x x x x x x x x x x x x
Rhabdomyolysis postmarketing, uncommon x x x
Thrombocytopenia postmarketing x
Urinary tract disorder postmarketing x x x x x x x x x x x
Hypophosphataemia postmarketing, very common x x x x x x x x x x x x
Acute interstitial nephritis postmarketing, rare x
Amylase increased postmarketing x x x x x x x x
Creatinine increased postmarketing, uncommon x x x x x x x x x x x x
Muscular weakness postmarketing, uncommon x x x
Bone pain postmarketing, rare x x x
Nephrogenic diabetes insipidus postmarketing, rare x x x x x x x x x
Malnutrition postmarketing x x x x x x x x x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing, 5% x x x x x x x
Hepatobiliary disease postmarketing x x x x x x x x x
Buffalo hump postmarketing x
Hyperlactacidaemia postmarketing x
Symptomatic hyperlactatemia postmarketing x
Renal impairment postmarketing x x x x x x x
Hepatic steatosis postmarketing, rare x x x
Anaemia x x
Anxiety x x x x x x x x
Arthralgia x x x x x x x x x x
Mental disorder x x x x x x
Hepatitis B x x
Metabolic disorder x x x x x x x x
Neuritis x x x x x x x x x x
Paraesthesia x x
Prurigo x
Sinusitis x x x x x
Urticaria x x x x x x x x x x
Rash pustular x x x x x x x x x x
Vesiculobullous rash x x x x x x x x x x
Alanine aminotransferase increased x
Haemoglobin decreased x
Rash macular x
Rash vesicular x
Abnormal dreams x x x x x x x
Rash maculo-papular x x x x x x x x x x
Neuropathy x x x x x x x x x x
Rash generalised x
Serum creatinine increased x
Infestation NOS x x x x x
Blood and lymphatic system disorders x
Exfoliative rash x
Somnolence x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

tenofovir disoproxil fumarate / VIREAD

Side effects:8
Source:FDA

tenofovir disoproxil fumarate / VIREAD

Side effects:17
Source:FDA

TENOFOVIR DISOPROXIL FUMARATE / VIREAD

Side effects:49
Source:FDA

tenofovir disoproxil fumarate / VIREAD

Side effects:49
Source:FDA

tenofovir disoproxil fumarate / Viread

Side effects:55
Source:FDA

TENOFOVIR DISOPROXIL FUMARATE / VIREAD

Side effects:55
Source:FDA

VIREAD tablets / Viread, Film coated tablet

Side effects:83
Source:Medsafe

TENOFOVIR DISOPROXIL FUMARATE / VIREAD

Side effects:69
Source:FDA

TENOFOVIR DISOPROXIL FUMARATE / VIREAD

Side effects:71
Source:FDA

tenofovir disoproxil fumarate / Viread

Side effects:72
Source:FDA

tenofovir disoproxil fumarate / Viread

Side effects:78
Source:FDA

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label